Experimental drug WSK-IM02 takes on Hard-to-Treat ovarian cancer
NCT ID NCT07462468
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental drug called WSK-IM02 in 36 women with platinum-resistant recurrent ovarian cancer, a type that no longer responds to standard platinum chemotherapy. The drug is given as an injection into the abdomen. The main goal is to check safety and find the right dose, with a secondary look at whether it might help shrink tumors. Because this is a Phase 1 study, it is too early to know if the drug will work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- WSK-IM02 (an experimental drug given by injection into the abdomen)
- What this could lead to
- If this early trial shows safety and hints of benefit, it could lead to a new treatment option for ovarian cancer that no longer responds to standard platinum chemotherapy.
- What could go wrong
- This is a very early Phase 1 study with only 36 participants. The main goal is safety, not effectiveness. Many experimental drugs fail at this stage, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.